Nevertheless, even these agents, dosed at therapeutic (rather than prophylactic) levels, are highly effective selectin inhibitors [ 56, 61].
These mean peak anti-FXa levels achieved with prophylactic-dose dalteparin are consistent with peak prophylactic levels of anticoagulation of 0.20 0.40 IU/ml observed in other hospitalized medical and surgical patients, indicating that our prophylaxis regimen had adequate bioavailability and an appropriate anticoagulant effect [ 20, 21].
The therapeutic and prophylactic target levels of anti-Xa activity are not supported by evidence of trials, but they are rather based on expert opinions [ 61, 62].
Based on these results, prophylactic PEEP levels inferior to the corresponding IAP can not be recommended in the setting of IAH as these PEEP levels are not sufficient in preventing FRC decline caused by IAH and may even be associated with a reduced DO2 as a consequence of a decreased CO.
Based on these results, prophylactic PEEP levels inferior to the corresponding IAP can not be recommended in the setting of IAH as these PEEP levels are not sufficient in preventing the FRC decline caused by IAH and may be associated with a reduced CO.
Table 7 shows prophylactic drugs with levels of recommendation I and II.
Since allergic-like reactions appeared with the lower dose levels, prophylactic antihistaminic medication (50 mg intramuscular diphenhydramine) was given 20 minutes before CIGB 300 injections to groups III and IV.
In prophylactic neck dissections where level III is less involved, level IIb dissection would lead to less likelihood of occult metastases.
Furthermore, in the present study, DVT occurred despite adequate levels of prophylactic anticoagulation, based on peak anti-FXa levels of approximately 0.30 IU/ml.
DVT occurred despite adequate levels of prophylactic anticoagulation: the median peak anti-FXa levels 2 hours and 4 hours after dalteparin administration were 0.29 (interquartile range, 0.19 to 0.39) based on 159 observations in 101 patients, and 0.31 (interquartile range, 0.22 to 0.43) based on 153 observations in 98 patients, respectively.
